Features and properties of Ivosidenib

Alternative names	AG-120; Tibsovo®
Class	Antineoplastics, cyclobutanes, nitriles, pyridines, pyrrolidines, small molecules
Mechanism of Action	Isocitrate dehydrogenase 1 inhibitor
Route of Administration	Oral
Pharmacodynamics	Selective, small molecule inhibitor of isocitrate dehydrogenase R132 mutants, resulting in the inhibition of mutant isocitrate dehydrogenase enzyme and decreased 2-hydroxyglutarate levels
Pharmacokinetics	Rapidly absorbed (median time to peak plasma concentration ≈ 3 h)
	Terminal elimination half-life 93 h
Adverse events in patients with acute myeloid leukaemia
Any-grade treatment-emergent	Diarrhoea, leucocytosis, febrile neutropenia, nausea, fatigue, dyspnoea, prolongation of the QT interval, peripheral oedema, anaemia, pyrexia, cough
Grade ≥ 3 treatment-related	Prolongation of QT interval, isocitrate dehydrogenase differentiation syndrome
ATC codes
WHO ATC code	L01X-X (Other antineoplastic agents)
EphMRA ATC code	L1X9 (All other antineoplastics)
Chemical Name	(2S)-N-[(1S)-1-(2-Chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide